Camurus

Camurus is an international biopharmaceutical company headquartered in Lund, Sweden, focused on developing and commercializing innovative long-acting medicines for severe and chronic diseases. Utilizing its proprietary FluidCrystal® technology, Camurus creates new drug products with best-in-class potential, particularly in the areas of CNS, endocrinology, and oncology. The company operates across Europe, the US, and Australia, and is listed on Nasdaq Stockholm under the ticker CAMX. Camurus is committed to improving patient outcomes through its extensive R&D pipeline and strategic partnerships.

285

12.09

11.35

— Camurus
%
Opioid Dependence Treatments50% Includes products like Buvidal® and Brixadi® for treating opioid use disorders.
Endocrinology Treatments25% Covers products like Oczyesa® for acromegaly and CAM2029 for endocrine disorders.
Oncology Treatments10% Includes pipeline products for cancer treatment.
Obesity and Diabetes Treatments10% Involves products like CAM2056 for obesity and diabetes management.
Drug Delivery Technology5% FluidCrystal® technology used for drug delivery solutions.

Camurus serves a diverse range of customers, primarily healthcare providers and pharmaceutical companies...

  • Healthcare Providersprimary

    Purchase products like Buvidal® for treating opioid dependence.

  • Pharmaceutical Companiessecondary

    Collaborate on product development and distribution.

  • Endocrinologistssecondary

    Use products like Oczyesa® for treating endocrine disorders.

  • Patient Advocacy Groupsemerging

    Support treatment adoption and market entry.

Camurus operates internationally with a strong presence in Europe, the US, and Australia...

  • •Headquartered in Lund, Sweden
  • •Strong presence in Europe, US, and Australia
  • •Key markets include Germany and Sweden for Buvidal® and Oczyesa®
  • •US market critical for Brixadi® launch
  • •Global operations supported by strategic partnerships

Camurus focuses on expanding its product portfolio and global market presence through strategic partnerships and...

01
Expand Product Portfoliomedium-term

To increase market reach and diversify offerings.

02
Leverage FluidCrystal® Technologylong-term

To develop innovative long-acting medications.

03
Successful Product Launchesshort-term

To capture market share and drive revenue growth.

Camurus faces several business and financial risks, including regulatory risks related to the approval of new drugs and...

critical

R&D Failures

Could result in sunk costs and lost opportunities.

Materiality
high
high

Regulatory Approval Delays

Could delay market entry and revenue generation.

Materiality
high
medium

Currency Fluctuations

Affect financial performance due to international operations.

Materiality
medium
Revenue Recognition
high
Currency Risk
medium
Share-Based Payments
medium

BRISTOL MYERS SQUIBB CO

BMY · Pharmaceutical Preparations

Xeris Biopharma Holdings, Inc.

XERS · Pharmaceutical Preparations

Amylyx Pharmaceuticals, Inc.

AMLX · Pharmaceutical Preparations

CUMBERLAND PHARMACEUTICALS INC

CPIX · Pharmaceutical Preparations

Mirum Pharmaceuticals, Inc.

MIRM · Pharmaceutical Preparations

Pacira BioSciences, Inc.

PCRX · Pharmaceutical Preparations

: 11/08/2026